

Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier		
	Trade name	:	Bezlotoxumab Formulation
1.2	Relevant identified uses of th	ie s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Piercetown A86 HD21 Dunboyne, Ireland
	Telephone	:	908-740-4000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Bezlotoxumab	1246264-45-8		>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.



Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

SECTION 5: Firefighting measures

5.1 Extinguishing media

	Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
	Unsuitable extinguishing media	:	None known.
5.2	Special hazards arising from Specific hazards during fire- fighting		e substance or mixture Exposure to combustion products may be a hazard to health.
	Hazardous combustion prod-	:	Carbon oxides

5.3 Advice for firefighters

ucts

Special protective equipment for firefighters	:	Wear self-contained breathing apparatus for firefighting if nec- essary. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures			
Personal precautions	:	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).	
6.2 Environmental precautions			
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.	

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	:	Soak up with inert absorbent material.
		For large spills, provide dyking or other appropriate contain-
		ment to keep material from spreading. If dyked material can

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Bezlotoxumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016
		Clean up rema bent. Local or nation posal of this ma employed in the mine which reg Sections 13 an	bre recovered material in appropriate container. ining materials from spill with suitable absor- al regulations may apply to releases and dis- aterial, as well as those materials and items e cleanup of releases. You will need to deter- gulations are applicable. d 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling					
Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.			
Local/Total ventilation	:	Use only with adequate ventilation.			
Advice on safe handling	:	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Take care to prevent spills, waste and minimize release to the environment.			
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.			
7.2 Conditions for safe storage,	inc	luding any incompatibilities			
Requirements for storage areas and containers	:	Keep in properly labelled containers. Store in accordance with the particular national regulations.			
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Gases			
7.3 Specific end use(s)					
Specific use(s)	:	No data available			

7.1 Precautions for safe handling

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Bezlotoxumab Formulation

Ver 2.1	sion Revision Da 28.09.2024			te of last issue: 06.04.2024 te of first issue: 22.07.2016	
	r	1	1		
	Components	CAS-No.	Value type (Form	Control parameters	Basis

		of exposure)		
Bezlotoxumab	1246264- 45-8	TWA	5.0 mg/m3 (OEB 1)	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	Aqueous solution
Colour	:	Colorless to pale yellow
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper	:	No data available



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Bezlotoxumab Formulation

Ver 2.1	sion	Revision Date: 28.09.2024		S Number: 3320-00024	Date of last issue: 06.04.2024 Date of first issue: 22.07.2016
	flamma	ability limit			
		explosion limit / Lower ability limit	:	No data available	9
	Flash p	point	:	No data available	e
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	рН		:	5.7 - 6.3	
	Viscos Vise	ity cosity, dynamic	:	1.2 mPa.s (25 °C)
	Vis	cosity, kinematic	:	1.833 mm2/s (4	°C)
				1.183 mm2/s (25	ö ℃)
		ity(ies) ter solubility	:	No data available	9
		on coefficient: n- I/water	:	Not applicable	
	Vapou	r pressure	:	No data available	e
	Relativ	e density	:	No data available	e
	Densit	y	:	1.0146 g/cm ³	
	Relativ	e vapour density	:	No data available	e
		e characteristics ticle size	:	Not applicable	
9.2	9.2 Other information			N 1 1 1	
	Explos		:	Not explosive	.,
		ng properties	:		r mixture is not classified as oxidizing.
	•	ration rate	:	No data available	
	Molecu	ılar weight	:	No data available	9



Commission Regulation (EU) 2020/878

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
2.1		818320-00024	Date of first issue: 22.07.2016

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Components:

Bezlotoxumab:

Acute toxicity (other routes of : LD50 (Mouse): > 125 mg/kg Application Route: Intraveno

LD50 (Mouse): > 125 mg/kg Application Route: Intravenous Remarks: No adverse effect has been observed in acute toxicity tests.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Bezlotoxumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Bezlotoxumab:

Species NOAEL Application Route Exposure time Remarks	:	Mouse 50 mg/kg Intravenous 15 d No significant adverse effects were reported
Species NOAEL Application Route Exposure time Remarks	: :	Mouse 125 mg/kg Intravenous 21 d No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Bezlotoxumab:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Bezlotoxumab Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
2.1		818320-00024	Date of first issue: 22.07.2016

SECTION 12: Ecological information

12.1 Toxicity

Inhalation

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

: Symptoms: Nausea, Headache, Diarrhoea, Fever

12.6 Endocrine disrupting properties

Product:

Assessment

The substance/mixture does not contain components consid-: ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Bezlotoxumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
ΙΑΤΑ	: Not regulated as a dangerous good
14.2 UN proper shipping	name
ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
ΙΑΤΑ	: Not regulated as a dangerous good
14.3 Transport hazard cl	ss(es)
ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
ΙΑΤΑ	: Not regulated as a dangerous good
14.4 Packing group	
ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA (Cargo)	: Not regulated as a dangerous good
IATA (Passenger)	: Not regulated as a dangerous good
14.5 Environmental haza	ds

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

		11011	
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable	
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable	
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable	
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable	
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable	

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

:

SECTION 16: Other information

Other information

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Bezlotoxumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

lines.

Full text of H-Statements

Full text of other abbreviations

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.1	28.09.2024	818320-00024	Date of first issue: 22.07.2016

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN